FentanylNCT07836595
Fentanyl Vs Dexmedetomidine as Adjuvants to Bupivacaine in Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Arthroscopic Shoulder Surgeries
A study testing Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg and Bupivacaine 0.25% + dexmedetomidine 1µg/kg in people with Fentanyl and Dexmedetomidine, run by Tanta University at 1 site in Egypt.
Trial summary
This study aimed to evaluate the effect of fentanyl versus dexmedetomidine as adjuvants to bupivacaine with comparison to bupivacaine alone in ultrasound-guided erector spinae plane block on the quality and duration of pain control in patients undergoing arthroscopic shoulder surgeries. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Fentanyl, Dexmedetomidine, Bupivacaine
- What is being tested?
- Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg and Bupivacaine 0.25% + dexmedetomidine 1µg/kg
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2024to 1 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Both sexes.
- Age from 21 to 60 years.
- Belonging to American Society of Anesthesiologists (ASA) physical status I and II.
- Underwent shoulder arthroscopic surgery.
Who cannot join
- Patients who were known to have an allergy to amide type local anesthetics, dexmedetomidine, or fentanyl.
- Patients who were receiving non-steroidal anti-inflammatory drugs or any chronic drugs for pain management in the past four weeks.
- Had a history of drug dependency or substance addiction.
- Body mass index (BMI) of 18.5 or higher.
- Had a severe spinal deformity.
- Had an uncontrolled concomitant medical condition.
- Had a local skin infection at the injection site or spinal metastasis.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Fentanyl Vs Dexmedetomidine as Adjuvants to Bupivacaine in Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Arthroscopic Shoulder Surgeries
This study aimed to evaluate the effect of fentanyl versus dexmedetomidine as adjuvants to bupivacaine with comparison to bupivacaine alone in ultrasound-guided erector spinae plane block on the quality and duration of pain control in patients undergoing arthroscopic shoulder surgeries.
Read the detailed description
Shoulder arthroscopic surgery is one of the most common surgical procedures performed in daily practice, for many surgical indications as rotator cuff tears, stiffness and instability, this procedure has a well - documented postoperative pain.
The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB has been used successfully in many surgeries such as mastectomy, thoracotomies, percutaneous nephrolithotomies, lumbar fusions, hernia repair, cesarean delivery and even in total hip arthroplasty.
Fentanyl as an additive to 0.25% bupivacaine in paravertebral block has been found to reduce the rescue analgesic consumption as well as cumulative pain scores at rest and on movement after breast surgery.
Dexmedetomidine is highly selective than clonidine, specific and potentα2-adrenergic agonist having analgesic, sedative, antihypertensive, and anesthetic sparing effects when used in systemic route.
- Conditions
- Fentanyl, Dexmedetomidine, Bupivacaine, Erector Spinae Plane Block, Postoperative Analgesia, Arthroscopic Shoulder Surgeries
- Being tested
- Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg, Bupivacaine 0.25% + dexmedetomidine 1µg/kg
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bupivacaine 0.25%Drug
Patients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2.
Bupivacaine 0.25% + Fentanyl 1µg/kgDrug
Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2.
Bupivacaine 0.25% + dexmedetomidine 1µg/kgDrug
Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2.
| Study group | Role | What they receive |
|---|---|---|
| ESPB with bupivacaine alone | Active comparator | Patients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2. Receives: Drug: Bupivacaine 0.25% |
| ESPB with Fentanyl group | Experimental | Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2. Receives: Drug: Bupivacaine 0.25% + Fentanyl 1µg/kg |
| ESPB with Dexmedetomidine group | Experimental | Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2. Receives: Drug: Bupivacaine 0.25% + dexmedetomidine 1µg/kg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of pain
Assessment of postoperative pain was done with numerical rate scale [numerical rate score (NRS); 0=no pain and 10=worst possible pain]. At post-anesthesia care unit (PACU) then 2, 4, 6, 8, 12, and 24 hours postoperative.
Measured: 24 hours postoperatively
Secondary outcomes (4)
Time of first rescue analgesia
Time of first rescue analgesia was recorded from the end of surgery till the first dose of morphine adminstrated.
Measured: 24 hours postoperatively
Intraoperative fentanyl consumption
Any intraoperative hypertension (mean arterial pressure>20% of baseline) or tachycardia were managed by rescue fentanyl dose 1µg /kg IV when suspected to be caused by intraoperative pain awareness and these cases was recorded.
Measured: Intraoperatively
Total amount of morphine consumption
Rescue analgesia in the form of 3 mg IV morphine was given if the numerical rate score (NRS) is ≥ 4 repeated with 10 minutes lockout interval till the (NRS) becomes less than 3.
Measured: 24 hours postoperatively
Length of hospital stay
Length of hospital stay was recorded from the admission till the discharge from hospital.
Measured: Till the discharge from hospital (Up to 2 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2026
- Study start1 Jan 2024
- Primary completion1 Dec 2024
- Study completion1 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FentanylStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Mohsen Kamel Sheta, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07836595
- Sponsor's protocol ID
- 36265MD170/11/23
- Status last verified
- Sep 2026
- First submitted
- 17 Sep 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Fentanyl Vs Dexmedetomidine as Adjuvants to Bupivacaine in Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Arthroscopic Shoulder Surgeries
- ClinicalTrials.gov ID
- NCT07836595
- Acronym / sponsor ID
- 36265MD170/11/23
- Conditions
- Fentanyl, Dexmedetomidine, Bupivacaine, Erector Spinae Plane Block, Postoperative Analgesia, Arthroscopic Shoulder Surgeries
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 1 Dec 2024 (actual)
- Study completion
- 1 Dec 2024 (actual)
- First posted
- 23 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the effect of fentanyl versus dexmedetomidine as adjuvants to bupivacaine with comparison to bupivacaine alone in ultrasound-guided erector spinae plane block on the quality and duration of pain control in patients undergoing arthroscopic shoulder surgeries.
Detailed description
Shoulder arthroscopic surgery is one of the most common surgical procedures performed in daily practice, for many surgical indications as rotator cuff tears, stiffness and instability, this procedure has a well - documented postoperative pain.
The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB has been used successfully in many surgeries such as mastectomy, thoracotomies, percutaneous nephrolithotomies, lumbar fusions, hernia repair, cesarean delivery and even in total hip arthroplasty.
Fentanyl as an additive to 0.25% bupivacaine in paravertebral block has been found to reduce the rescue analgesic consumption as well as cumulative pain scores at rest and on movement after breast surgery.
Dexmedetomidine is highly selective than clonidine, specific and potentα2-adrenergic agonist having analgesic, sedative, antihypertensive, and anesthetic sparing effects when used in systemic route.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| ESPB with bupivacaine alone | Active comparator | Drug: Bupivacaine 0.25%Patients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2. |
| ESPB with Fentanyl group | Experimental | Drug: Bupivacaine 0.25% + Fentanyl 1µg/kgPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2. |
| ESPB with Dexmedetomidine group | Experimental | Drug: Bupivacaine 0.25% + dexmedetomidine 1µg/kgPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Both sexes.
- Age from 21 to 60 years.
- Belonging to American Society of Anesthesiologists (ASA) physical status I and II.
- Underwent shoulder arthroscopic surgery.
Key exclusion criteria (7 listed)
- Patients who were known to have an allergy to amide type local anesthetics, dexmedetomidine, or fentanyl.
- Patients who were receiving non-steroidal anti-inflammatory drugs or any chronic drugs for pain management in the past four weeks.
- Had a history of drug dependency or substance addiction.
- Body mass index (BMI) of 18.5 or higher.
- Had a severe spinal deformity.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bupivacaine 0.25%Patients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2. | Drug | ESPB with bupivacaine alone |
| Bupivacaine 0.25% + Fentanyl 1µg/kgPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2. | Drug | ESPB with Fentanyl group |
| Bupivacaine 0.25% + dexmedetomidine 1µg/kgPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2. | Drug | ESPB with Dexmedetomidine group |
Primary outcome
Degree of pain
Time frame: 24 hours postoperatively
Assessment of postoperative pain was done with numerical rate scale [numerical rate score (NRS); 0=no pain and 10=worst possible pain]. At post-anesthesia care unit (PACU) then 2, 4, 6, 8, 12, and 24 hours postoperative.
4 secondary outcomes
Time of first rescue analgesia
Time frame: 24 hours postoperatively
Intraoperative fentanyl consumption
Time frame: Intraoperatively
Total amount of morphine consumption
Time frame: 24 hours postoperatively
Length of hospital stay
Time frame: Till the discharge from hospital (Up to 2 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Fentanyl
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Active, not recruitingPhase 1
Comparison of Analgesic Efficacy Between Ultrasound Guided Serratus Anterior Plane Block or Thoracic Paravertebral Block Versus Intravenous Fentanyl for On-pump Coronary Artery Bypass Graft Surgery
Intra and Post Operative Pain Management, Fast Track Program,(Enhanced Recovery After Surgery (ERAS))
Not yet recruiting
Remote Intervention to Prevent Overdose
Accidental Overdose of Opiate
RecruitingPhase 1
MethaLoad Dose-Finding Study
Opioid Use Disorder (OUD)
Recruiting
Comparison of the Effectiveness of Midpoint Transverse Process to Pleura (MTP) Block and Erector Spinae Plane (ESP) Block in Video-Assisted Thoracoscopic Surgery (VATS) at RS Ngoerah
Pain, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg and Bupivacaine 0.25% + dexmedetomidine 1µg/kg in people with Fentanyl and Dexmedetomidine, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of pain (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026.